Incyte raises 2024 sales forecast for top-selling drug Jakafi
Incyte beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong.
Incyte (INCY) Q3 Earnings Miss Estimates
Incyte (INCY) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.10 per share a year ago.
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Truist Securities has downgraded Incyte Corporation INCY, noting Jakafi's (ruxolitinib) patent loss approaching in 2028.
Incyte Announces Promising New Data on Oncology Candidate at ESMO
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License Application filing for label expansion of Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma, expected by end of 2024. It is expected that the 7 major follicular lymphoma markets are expected to reach a value of $2.2 billion by 2034.
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
On Friday, Incyte Corporation INCY released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituximab compared with lenalidomide alone as an add-on to rituximab in patients with relapsed or refractory follicular lymphoma or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL).
Incyte's blood cancer drug succeeds late-stage trial
Incyte said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.
FDA approves Incyte's treatment for chronic graft-versus-host disease
The U.S. Food and Drug Administration on Wednesday approved drugmaker Incyte Corp's treatment for a type of graft-versus-host disease (GvHD).
